[Psychoneurotic dysfunctions as side effect of antihypertensive agents].
First Department of Pharmacology, Hokkaido University School of Medicine.
H
H
Togashi
H
H
Saito
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D009497:Neurotic Disorders / Q000139:chemically induced*; D011788:Quality of Life; D013565:Sympatholytics / Q000009:adverse effects; D014665:Vasodilator Agents / Q000009:adverse effects
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D013565:Sympatholytics; D014665:Vasodilator Agents